Organon (OGN) Amortizatization of Intangibles (2020 - 2026)
Organon (OGN) posted quarterly Amortizatization of Intangibles of $46.0 million for Q2 2026, down 13.21% year-over-year from $53.0 million in Q2 2025, and down 2.13% on a QoQ basis from $47.0 million in Q1 2026.
Organon (OGN) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Organon has reported Amortizatization of Intangibles for 7 years, with the latest figure at $46.0 million in Q2 2026.
- Amortizatization of Intangibles for Q2 2026 came in at $46.0 million, down 13.21% year-over-year; the trailing twelve-month figure through Jun 2026 was $195.0 million (up 7.73% YoY), and the FY2025 annual result was $205.0 million, up 41.38% from the prior year.
- Amortizatization of Intangibles retreated to $46.0 million in Q2 2026, from $47.0 million in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $53.0 million in Q2 2025 and troughed at $28.0 million in Q1 2022.
- A 5-year average of $37.5 million and a median of $33.5 million in 2024 frame the typical range for Amortizatization of Intangibles.
- The widest annual swing landed in 2022, when Amortizatization of Intangibles declined 17.65%; it then surged 55.88% in 2025.
- A 5-year view of Amortizatization of Intangibles shows it stood at $28.0 million in 2022, then changed by 0.0% to $28.0 million in 2023, then soared by 53.57% to $43.0 million in 2024, then climbed by 16.28% to $50.0 million in 2025, then slipped by 8.0% to $46.0 million in 2026.
- Per Business Quant data, the three most recent Amortizatization of Intangibles figures were $46.0 million in Q2 2026, $47.0 million in Q1 2026, and $50.0 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 984.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 600.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn | 46.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.00 Mn |
| Jun 30, 2026 | 46.00 Mn |
| Mar 31, 2026 | 47.00 Mn |
| Mar 31, 2026 | 47.00 Mn |
| Dec 31, 2025 | 50.00 Mn |
| Dec 31, 2025 | 50.00 Mn |
| Sep 30, 2025 | 52.00 Mn |
| Sep 30, 2025 | 52.00 Mn |
| Jun 30, 2025 | 53.00 Mn |
| Jun 30, 2025 | 53.00 Mn |
| Mar 31, 2025 | 50.00 Mn |
| Mar 31, 2025 | 50.00 Mn |
| Dec 31, 2024 | 43.00 Mn |
| Dec 31, 2024 | 43.00 Mn |
| Sep 30, 2024 | 35.00 Mn |
| Sep 30, 2024 | 35.00 Mn |
| Jun 30, 2024 | 34.00 Mn |
| Jun 30, 2024 | 34.00 Mn |
| Mar 31, 2024 | 33.00 Mn |
| Mar 31, 2024 | 33.00 Mn |